1461051115-91d52e78-1b0d-4b3d-937a-901f67ea37b5

1. A method of treating a proliferative disease in an individual, comprising administering to the individual: a) an effective amount of a composition comprising nanoparticles comprising taxane and a carrier protein, and b) an effective amount of an anti-VEGF antibody.
2. The method of claim 1, wherein the effective amounts of the nanoparticle composition and the anti-VEGF antibody synergistically inhibit cell proliferation.
3. The method of claim 1, wherein the proliferative disease is cancer.
4. The method of claim 3, wherein the cancer is breast cancer.
5. The method of claim 1, wherein the anti-VEGF antibody is bevacizumab.
6. The method of claim 1, wherein the effective amount of the anti-VEGF antibody is at least about 2 mgkg.
7. The method of claim 6, wherein the effective amount of the anti-VEGF antibody is at least about 4 mgkg.
8. The method of claim 1, wherein the amount of taxane in the nanoparticle composition is at least about 10 mgkg.
9. The method of claim 1, wherein the nanoparticle composition and the anti-VEGF antibody are administered sequentially to the individual.
10. The method of claim 1, wherein the nanoparticle composition is administered for at least one cycles prior to the administration of the anti-VEGF antibody.
11. The method of claim 10, wherein the administration of the nanoparticle composition is followed by the administration of an anti-VEGF antibody for at least about 3 weeks.
12. The method of claim 1, wherein the method comprises administration of 200 mgm2 taxane in a nanoparticle composition at least weekly concurrent with administration of 10 mgkg anti-VEGF antibody every two weeks.
13. The method of claim 1, wherein the taxane is paclitaxel.
14. The method of claim 1, wherein the average diameter of the nanoparticles in the composition is no greater than about 200 nm.
15. The method of claim 1, wherein the carrier protein is albumin.
16. The method of claim 15, wherein the weight ratio of the albumin and the taxane in the nanoparticle composition is less than about 9:1.
17. The method of claim 1, wherein the nanoparticle composition is free of Cremophor.
18. The method of claim 1, wherein the individual is human.
19. A method of inhibiting tumor metastasis in an individual, comprising administering to the individual: a) an effective amount of a composition comprising nanoparticles comprising taxane and a carrier protein, and b) an effective amount of an anti-VEGF antibody.
20. The method of claim 19, wherein the effective amounts of the nanoparticle composition and the anti-VEGF antibody synergistically inhibit tumor metastasis.
21. The method of claim 19, wherein the tumor metastasis is metastasis to lymph node.
22. The method of claim 19, wherein the tumor metastasis is metastasis to the lung.
23. The method of claim 19, wherein the tumor metastasis is metastasis of breast cancer.
24. The method of claim 19, wherein the anti-VEGF antibody is bevacizumab.
25. The method of claim 19, wherein the effective amount of the anti-VEGF antibody is at least about 2 mgkg.
26. The method of claim 25, wherein the effective amount of the anti-VEGF antibody is at least about 4 mgkg.
27. The method of claim 19, wherein the amount of taxane in the nanoparticle composition is at least about 10 mgkg.
28. The method of claim 19, wherein the nanoparticle composition and the anti-VEGF antibody are administered sequentially to the individual.
29. The method of claim 19, wherein the nanoparticle composition is administered for at least one cycles prior to the administration of the anti-VEGF antibody.
30. The method of claim 29, wherein the administration of the nanoparticle composition is followed by the administration of an anti-VEGF antibody for at least about 3 weeks.
31. The method of claim 19, wherein the method comprises administration of 200 mgm2 taxane in a nanoparticle composition at least weekly concurrent with administration of 10 mgkg anti-VEGF antibody every two weeks.
32. The method of claim 19, wherein the taxane is paclitaxel.
33. The method of claim 19, wherein the average diameter of the nanoparticles in the composition is no greater than about 200 nm.
34. The method of claim 19, wherein the carrier protein is albumin.
35. The method of claim 34, wherein the weight ratio of the albumin and the taxane in the nanoparticle composition is less than about 9:1.
36. The method of claim 19, wherein the nanoparticle composition is free of Cremophor.
37. The method of claim 19, wherein the individual is human.
38. The method of claim 19, wherein at least about 40% of metastasis is inhibited.
39. The method of claim 19, wherein at least about 80% of metastasis is inhibited.

The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.

1. An ophthalmic apparatus comprising:
a fundus observation optical system including an image pickup element to observe a fundus of an examinee’s eye, the fundus observation optical system being configured to obtain a fundus image of the eye;
a target presenting optical system for presenting a fixation target and an examination target to the eye;
a designating part for designating an area of the fundus having a visual function other than a macular area from the fundus image displayed on a monitor;
a setting part for setting a distinctive portion of the fundus other than the designated fundus area from the fundus image displayed on the monitor, and associating a positional relationship between the set distinctive portion of the fundus with the fundus area designated by the designating part;
a judging part for detecting an approaching state of the designated fundus area designated by the designating part and the fixation target based on the distinctive portion of the fundus set by the setting part and the presented fixation target and the associated positional relationship, and judging whether the fundus area and the fixation target are coincident in a predetermined allowable range; and
a display control part for changing a display state of the fixation target by fixing a presenting position of the fixation target when the judging part judges that the fundus area and the fixation target are coincident in the predetermined allowable range.
2. The ophthalmic apparatus according to claim 1, wherein the display control part forms an index on the monitor to represent a position of the fundus area and changes position of the formed index based on a detection result of the judging part.
3. The ophthalmic apparatus according to claim 2, further comprising:
a memory for storing examinee information, information of the distinctive portion of the fundus, and positional information of the fundus area by associating the informations with each other; and
a retrieval part for retrieving, from the memory, the examinee information, the information of the distinctive portion of the fundus and the positional information of the fundus area, wherein
the display control part forms the index on the monitor based on the information of the distinctive portion of the fundus and the positional information of the fundus area when the retrieval part retrieves the examinee information.
4. The ophthalmic apparatus according to claim 3, wherein the judging part extracts the distinctive portion of the fundus from the fundus image displayed on the monitor.
5. The ophthalmic apparatus according to claim 4, wherein the display control part switches a shape of the fixation target to a checker flag pattern consisting of white areas and black areas alternately arranged when the fundus area and the fixation target are substantially coincident with each other.
6. The ophthalmic apparatus according to claim 5, wherein the display control part selectively blinks the white areas and the black areas of the fixation target in the checker flag pattern.
7. The ophthalmic apparatus according to claim 6, further comprising:
a speaker to generate a sound; and
an information control part for controlling the speaker to generate an information sound when the judging part judges that the fixation target and the fundus area are coincident within the predetermined allowable range.
8. The ophthalmic apparatus according to claim 7, wherein
the information control part (1) changes a sound volume of the information sound generated from the speaker or (2) generates the sound based on a detection result of the approaching state of the fixation target and the fundus area by the judging part, and
when the fixation target and the fundus area are substantially coincident with each other, the sound volume of the sound generated from the speaker is maximized or the generated sound is minimized.